Article Information
History
- July 19, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Caihua Liang1,*,
- Aleksandra Polkowska-Kramek2,
- Caroline Lade3,
- Lea Johanna Bayer3,
- Robin Bruyndonckx2,
- Bennet Huebbe3,
- Worku Biyadgie Ewnetu2,
- Pimnara Peerawaranun2,
- Maribel Casas2,
- Thao Mai Phuong Tran2,
- Gordon Brestrich3,
- Christof von Eiff3,
- Bradford D. Gessner1,
- Elizabeth Begier4 and
- Gernot Rohde5
- 1Pfizer Inc-New York (USA)
- 2P95 Epidemiology & Pharmacovigilance, Leuven, Belgium
- 3Pfizer Pharma GmbH - Berlin (Germany)
- 4Pfizer Inc - Dublin (Ireland)
- 5Goethe University Frankfurt, University Hospital, Medical Clinic I, Department of Respiratory Medicine, Frankfurt/Main, Germany
- ↵*Corresponding author:
Caihua Liang, Email: caihua.liang{at}pfizer.com, Address: 66 Hudson Blvd E, New York, NY 10001
Posted July 19, 2024.
Estimated incidence rate of specific cardiovascular and respiratory hospitalizations attributable to Respiratory Syncytial Virus among adults in Germany between 2015 and 2019
